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ABSTRACT
Objective Today most patients with Lynch syndrome
(LS) survive their ﬁrst cancer. There is limited information
on the incidences and outcome of subsequent cancers.
The present study addresses three questions: (i) what is
the cumulative incidence of a subsequent cancer; (ii) in
which organs do subsequent cancers occur; and (iii)
what is the survival following these cancers?
Design Information was collated on prospectively
organised surveillance and prospectively observed
outcomes in patients with LS who had cancer prior to
inclusion and analysed by age, gender and genetic
variants.
Results 1273 patients with LS from 10 countries were
followed up for 7753 observation years. 318 patients
(25.7%) developed 341 ﬁrst subsequent cancers,
including colorectal (n=147, 43%), upper GI, pancreas or
bile duct (n=37, 11%) and urinary tract (n=32, 10%).
The cumulative incidences for any subsequent cancer from
age 40 to age 70 years were 73% for pathogenic MLH1
(path_MLH1), 76% for path_MSH2 carriers and 52% for
path_MSH6 carriers, and for colorectal cancer (CRC) the
cumulative incidences were 46%, 48% and 23%,
respectively. Crude survival after any subsequent cancer
was 82% (95% CI 76% to 87%) and 10-year crude
survival after CRC was 91% (95% CI 83% to 95%).
Conclusions Relative incidence of subsequent cancer
compared with incidence of ﬁrst cancer was slightly but
insigniﬁcantly higher than cancer incidence in patients
with LS without previous cancer (range 0.94–1.49). The
favourable survival after subsequent cancers validated
continued follow-up to prevent death from cancer. The
interactive website http://lscarisk.org was expanded to
calculate the risks by gender, genetic variant and age for
subsequent cancer for any patient with LS with previous
cancer.
INTRODUCTION
Lynch syndrome (LS) is associated with a high
probability of GI, gynaecological and other
cancers.1 2 It is caused by germline pathogenic var-
iants in any of the four DNA mismatch repair
Signiﬁcance of this study
What is already known on this subject?
▸ Inherited colorectal cancer may be caused by
mismatch repair (MMR) gene variants and is
then commonly referred to as Lynch syndrome.
▸ Patients with Lynch syndrome are at risk for
synchronous and metachronous cancers.
▸ Endoscopic surveillance with removal of
adenomas is recommended to prevent
colorectal cancer.
What are the new ﬁndings?
▸ This is the ﬁrst comprehensive prospective
study to provide empirically observed data on
subsequent cancer incidence and survival in
patients with Lynch syndrome who have
survived previous cancer.
▸ The cumulative incidences for any subsequent
cancer were 73% for path_MLH1 and 76% for
path_MSH2 carriers. The incidence was lower
in MSH6 carriers.
▸ Colorectal cancer occurred frequently despite
continued colonoscopic surveillance with
removal of adenomas.
▸ Survival after subsequent cancer was good.
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(MMR) genes. Such variants are here referred to as
path_MSH2, path_MLH1, path_PMS2 or path_MSH6.
Deletions in the EP CAM gene, which lead to methylation of
the adjacent MSH2 promoter, are also referred to here as
path_MSH2. To date, most patients with LS have been identiﬁed
following investigation because of their family or personal
history of multiple and/or early-onset cancers.
Screening by colonoscopy is recommended to prevent colo-
rectal cancer (CRC) by removing preinvasive neoplasia (aden-
omas).1 2 Carriers of path_MLH1, path_MSH2, path_MSH6 or
path_PMS2 require reliable information about their future
cancer risk so that they can be offered appropriately targeted
surveillance. However, a paucity of prospectively obtained infor-
mation has led current clinical guidelines to rely heavily upon
retrospective data from patient cohorts whose selection for
molecular testing has been subject to diverse biases.
We have previously reported prospectively observed time to
ﬁrst cancer by mutated gene and gender in asymptomatic
patients with LS undergoing follow-up including colonoscopy.3
CRC occurred with high incidence despite endoscopic surveil-
lance with removal of adenomas. However, survival was excel-
lent for patients with invasive CRC and for patients with
endometrial and ovarian cancer.
The assumptions underlying current guidelines for healthcare
for patients with LS, to which we have contributed,1 should be
replaced by empirical observations whenever possible. However,
there is limited empirical information from prospective studies
on the outcomes for patients with LS who have survived a ﬁrst
cancer and are receiving continued surveillance according to
existing guidelines.4
We designed the present study to address three questions in
patients with LS who had survived previous cancer and were at
risk of developing subsequent cancers: (i) what was the cumula-
tive incidence of subsequent cancers, (ii) in which organs did
subsequent cancers occur and (iii) what was survival following
these subsequent cancers?
METHODS
Patients and interventions
Database design and inclusion criteria have been described pre-
viously.3 The study was a case-based, open observational study
without a control group. All patients were 20 years of age or
older at inclusion. Age at inclusion was age at the ﬁrst prospect-
ively planned colonoscopy. We included all patients with LS
who survived their previous cancer(s) and continued to have
surveillance with the aim of preventing death from a subsequent
cancer. Inclusion was from the day of the ﬁrst prospectively
planned and completed colonoscopy undertaken as part of the
patient’s follow-up surveillance.
The patients with LS included in this report were demon-
strated or obligate carriers of pathogenic MMR variants who
had been diagnosed with cancer before or at the same age as
when included (referred to as ‘previous cancer’ later). All
patients had at least one previous cancer before or at inclusion.
Prevalent cancers including all cancers in the colorectum or any
other organ that were diagnosed at the same age as the ﬁrst pro-
spectively planned and completed colonoscopy following a pre-
vious cancer were also scored as previous cancers. All incident
cancers reported here were detected after the ﬁrst prospectively
planned colonoscopy. All patients were considered survivors of
ﬁrst cancer(s) and subjected to follow-up for prevention or early
treatment of a possible subsequent new cancer. All patients were
subjected to follow-up including surveillance colonoscopy
according to international guidelines.1 2 Follow-up was con-
ducted as previously reported (see details in online supplemen-
tary table S2 with references). In brief, the interval between
colonoscopies was reduced circa 1996 to 2 years or less in
keeping with new international guidelines by all reporting
centres except those in Finland. A detailed analysis comparing
outcomes in the Finnish series to the rest is in preparation and
will be reported separately.
All patients had MMR variants that were considered patho-
genic by the contributing centre at the time of reporting to the
database. To validate this judgement, all reported genetic var-
iants were independently searched for in the Leiden Open
Variation Database (LOVD) (http://chromium.lovd.nl/LOVD2/
colon_cancer/) in October 2015. Deletions in the EP CAM gene
silencing MSH2 were scored as path_MSH2 variants. In sum
617 of the patients had pathogenic (class 5) variants, 14 patients
had probably pathogenic (class 4) variants and the remaining
642 patients had variants that were not found in LOVD.
The patients were followed until the last update of informa-
tion, and scored as alive or dead at last update. The following
information was used for this report: gender, genetic variant,
age at inclusion, age at last update, age at any cancer, months
since last colonoscopy to CRC, cancers scored by the ﬁrst three
positions in the ICD9 diagnostic system and age of death. The
ICD9 diagnoses were copied from the medical ﬁles. All cancer
diagnoses were included to avoid assumptions on which cancers
to be part of LS to bias the results. Cancer stage at diagnosis
was not available. Data were complete for all patients included
except for eight patients who lacked data on months since last
colonoscopy to CRC. Cancers diagnosed after the ﬁrst subse-
quent cancer were not considered. When calculating time to
subsequent cancer and survival, each patient was scored once
only, irrespective of how many synchronous subsequent cancers
the patient might have had.
The extent of surgery for previous CRC before inclusion may
inﬂuence the incidence of subsequent CRC. In general, patients
with colon cancer prior to inclusion would not have been recog-
nised as LS and would have been subjected to standard treat-
ment. Also, subtotal colectomy as treatment for a ﬁrst colon
cancer in LS has not been advocated widely in Europe.1 The
risk of a subsequent CRC may differ in patients subjected to
subtotal colectomy compared with those who had less extensive
surgery. We did not have access to details of surgical treatment
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ The good survival of the prospectively detected cancers in
our cohort supports continued medical follow-up including
colonoscopy and promotion of cancer awareness, which may
contribute to favourable outcomes in this high-risk group
through early detection and treatment of cancers.
▸ The high incidence of a subsequent colon cancer after a ﬁrst
colon cancer may be an argument in favour of subtotal
colectomy as treatment for ﬁrst colon cancer.
▸ The freely available website http://lscarisk.org may be used
to calculate risk for subsequent cancer in survivors of ﬁrst
cancer(s) using the patient’s gender, pathogenic MMR gene
variant and current age.
2 Møller P, et al. Gut 2016;0:1–8. doi:10.1136/gutjnl-2016-311403
GI cancer
group.bmj.com on October 7, 2016 - Published by http://gut.bmj.com/Downloaded from 
of previous CRC, but we were interested to see whether the
numbers observed in this study might allow planning of
follow-up studies taking into account treatment for previous
cancers, time from last colonoscopy to CRC and ﬁndings at last
colonoscopy together with stage at diagnoses of CRC and the
relations between these parameters and survival, all stratiﬁed by
genetic variants. Additional confounding factors include modi-
ﬁed risk for subsequent cancer following treatment with radi-
ation or chemotherapy. Unfortunately, such information was not
uniformly ﬁled and/or not available from all the collaborating
centres. We decided to analyse the dataset without discriminat-
ing between modes of treatment for any cancer, and the results
must be interpreted accordingly.
Some centres have reported their prospective ﬁndings inde-
pendently and their previously reported cases are included in
the present series—see ref. 3 and online supplementary table S2
for a list of previous publications.
Statistical methods
Annual incidence rates (AIRs) by age were calculated in 5-year
cohorts from 25 to 69 years of age. Cumulative incidence,
denoted by Q, was computed starting at age 25, assuming zero
incidence before age 25, using the formula Q(age)=Q(age−1)+
(1−Q(age−1))·AIR(age) where AIR(age) is the AIR as estimated
from the corresponding 5-year interval. SE for the AIR was esti-
mated as SEAIR=sqrt(AIR·(1−AIR)/Yrs) where Yrs denotes the
number of observation years in the 5-year age group for which
the AIR is estimated. For cumulative incidence, the hazard rate
H=−ln(1−AIR) was used with SE estimated as SEH=SEAIR/(1
−AIR). The SE, denoted by SEQ, of the cumulative incidence Q
(age) up to the given age is computed in two steps. First, for
each 5-year age interval, having hazard rate H with SE SEH, the
contribution to the cumulative hazard from that interval is N·H
with SE N·SEH where N is the number of years from that
5-year interval: for example, the cumulative incidence up to age
32 contains all 5 years from the 25–29 age interval, but only
3 years from the 30–34 age interval. The accumulated hazard
CH is computed by adding the N·H values across age intervals,
while the corresponding SE, SECH, is found by setting SECH2
equal to the sum of (N·SEH) across age intervals. The accumu-
lated hazard rate CH should now equal −ln(1−Q) with Q as
computed above, while the SE of the cumulative incidence is
computed as SEQ=SECH·(1−Q). We estimated 95% CIs as AIR
±1.96 SEAIR and Q±1.96 SEQ.
In contrast to our former report that focused on the pene-
trance of the pathogenic variants of the different MMR genes3
this report focuses on cumulative cancer incidence from the age
at which the previous cancer(s) was treated, and the results are
presented by age at inclusion. In clinical practice, these ﬁgures
provide the basis for improved advice for patients with LS who
have been treated for cancer and now wish to know his/her risk
of subsequent cancer. Cumulative incidences in this series rela-
tive to our former report3 on patients with LS who had not had
cancer before inclusion were calculated as cumulative incidence
in this report divided by corresponding cumulative incidence in
the former report.
The cumulative incidences in this report may be considered
prospective risks for cancer when discussing outcome of predict-
ive genetic testing, and the interactive website http://lscarisk.org,
which was established previously based on our former report,
was expanded to display the future cancer risk for any patient
with LS who has already had cancer, by age, sex and genetic
variant.
Crude survival after the ﬁrst subsequent cancer to be
diagnosed was assessed by the Kaplan–Meier survivor function
(K–M). Results of K–M analyses are given as point estimates
(95% CI). Two-by-two tables were considered by Fisher’s exact
p. For comparisons of groups twosample t-test, χ2 test and
Fisher’s exact p test were used as appropriate.
Ethics
All genetic tests were done with appropriate informed consent
according to local and national requirements for healthcare and/
or research. No named data were exported from any participat-
ing centre.
RESULTS
A total of 1273 patients with LS including 555 males and 718
females, with cancer before or at inclusion, were observed for
4411 years (mean 6.1 years) in females and 3342 years (mean
6.0 years) in males. Mean age at inclusion was 51.6 years. Mean
ages at inclusion were similar for path_MLH1 and path_MSH2
carriers (51.0 and 50.0, respectively), but older for path_MSH6
and path_PMS2 carriers (57.6 and 55.9, respectively). For
details on numbers included, observation years, mean observa-
tion years and mean ages at inclusion by country, gene and
gender see table 1. The number of path_PMS2 carriers was too
small to allow detailed statistical calculations.
Prior to inclusion, the 1273 patients had developed 1835
cancers (mean 1.4 per patient), with CRCs accounting for 1161
Table 1 Number of cases, observation years and age at inclusion
stratified on country of origin, genetic variant and gender
Observation years Age at inclusion
Number Total
Mean
(range)
95% CI
of mean
Mean
(range)
95% CI
of mean
ALL 1273 7753 6.1 (1–29) ±0.24 51.6 (21–95) ±0.68
Females 718 441 6.1 (1–29) ±0.33 52.7 (21–95) ±0.88
Males 555 3342 6.0 (1–27) ±0.36 50.3 (21–91) ±1.04
Grouped by country
Finland 365 2653 7.3 (1–24) ±0.50 53.6 (25–95) ±1.25
UK 195 988 5.1 (1–16) ±0.51 51.0 (21–82) ±1.71
Denmark 181 1004 5.5 (1–15) ±0.49 52.0 (24–83) ±1.70
Spain 141 743 5.3 (1–13) ±0.60 51.4 (24–89) ±2.08
Germany 126 650 5.2 (1–29) ±0.73 45.1 (21–71) ±1.88
Norway 108 684 6.3 (1–19) ±0.92 55.6 (27–83) ±2.20
Sweden 61 455 7.5 (1–27) ±1.31 52.8 (29–77) ±3.11
Holland 55 238 4.3 (1–19) ±1.18 51.6 (22–82) ±3.71
Australia 35 293 8.4 (1–26) ±1.95 44.9 (22–70) ±3.56
Italy 6 45 7.5 (2–11) ±3.46 42.7 (33–55) ±5.67
Grouped by gene and gender
path_MLH1
Females 305 2172 7.1 (1–29) ±0.55 52.0 (21–84) ±1.42
Males 284 1906 6.7 (1–21) ±0.52 49.8 (23–91) ±1.45
path_MSH2
Females 285 1502 5.3 (1–19) ±0.45 51.6 (22–83) ±1.27
Males 185 1085 5.9 (1–27) ±0.65 47.5 (21–73) ±1.56
path_MSH6
Females 109 669 6.1 (1–19) ±0.86 57.6 (27–95) ±2.38
Males 58 265 4.6 (1–13) ±0.75 57.6 (33–83) ±3.44
path_PMS2
Females 19 68 3.6 (1–13) ±1.41 52.0 (37–68) ±4.05
Males 28 86 3.1 (1–10) ±0.93 58.5 (27–77) ±4.80
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(63%) of all previous cancers. CRCs represented 83% of
cancers diagnosed in males and 49% of the cancers in females.
Endometrial (n=296) and ovarian (n=61) cancers accounted
for 28% and 6%, respectively, of all previous cancers in
females. Urinary tract (n=80), breast (n=46), upper GI tract
(n=41) and prostate (n=21) cancers were also frequently
reported. The separate diagnoses by gender are given in table 2.
Out of the 1273 patients, 392 (31%) had had two or more pre-
vious tumours: 268 (21%) had two, 91 (7%) had three, 22
(2%) had four, 9 (1%) had ﬁve, one (0.1%) had six and one
(0.1%) had seven cancers before inclusion.
Spectrum of cancers diagnosed during follow-up
During follow-up 318 (25.7%) patients developed a subsequent
cancer. In a minority of cases (n=18; 6%) two synchronous
cancers were diagnosed: one patient had both a duodenal
cancer and two skin cancers, and one had one colon cancer and
three skin cancers. Skin cancers (excluding malignant melano-
mas) are often not reported and ﬁgures for skin cancers in the
current report should be interpreted with caution. ICD9 diagno-
sis and gender of the 341 subsequent cancers are detailed in
table 3. CRCs (n=147; 43%), mainly colonic, were the most
frequent cancers and were diagnosed in males and females at
similar frequencies. Other frequent cancers included urinary
tract (n=32), stomach (n=14), duodenum (n=9), pancreas
(n=8), gall bladder (n=6) and brain tumours (n=7).
Prostate cancer (n=20, 4%) was the second most frequent
cancer in males. In females, endometrial (n=30) and breast
(n=15) cancers were also frequently detected. Of note, 336 of
718 (47%) females had endometrial and/or ovarian cancer
before inclusion and an additional 59 (8%) had undergone hys-
terectomy and/or oophorectomy without having had endomet-
rial or ovarian cancer. In addition, 20 (3%) had been treated for
cervical cancer. Because of low numbers of gynaecological
cancers, as well as possible selection artefacts due to previous
hysterectomies, we estimated neither cumulative incidence nor
survival of endometrial or ovarian cancers.
The mean age at diagnosis for the ﬁrst subsequent cancer was
58.8 years (range 28–90 years). Notably, 48 of these subsequent
cancers (15%) occurred after 70 years of age. Age at inclusion
was similar for path_MLH1 and path_MSH2 carriers and
similar for males and females. Because of the similar frequencies
of CRC in males and females (table 3), both genders were con-
sidered as one group for calculation of cumulative CRC
incidences.
Cumulative incidences of subsequent cancers
AIR of cancer in 5-year cohorts from age 25–70 years were cal-
culated for any cancer and for CRC (table 4). The 10 patients
included aged 20–24 years had no subsequent cancers before
25 years of age. AIRs at >70 years were not calculated since
patients aged >70 years might not have been subjected to sys-
tematic colonoscopic surveillance in all centres.
Table 3 First subsequent cancers diagnosed
ICD9 Organ Males Females All
153 Colon 57 57 114
154 Rectum/sigmoid 20 13 33
182 Endometrium 30 30
183 Ovary 7 7
151 Stomach 9 5 14
152 Duodenum 5 4 9
156 Gall bladder/bile duct 4 2 6
157 Pancreas 4 4 8
188 Urinary bladder 5 9 14
189 Kidney/ureter 8 10 18
173 Skin* 13 14 27
174 Breast 15 15
185 Prostate 20 20
191 Brain 2 5 7
141 Tongue 1 1
145 Mouth 1 1
155 Liver 1 1 2
159 Abdomen unspecified 1 1
162 Lung 3 1 4
164 Mediastinum 1 1
170 Osteosarcoma 2 2
172 Melanoma 1 1
180 Cervix 1 1
199 Unknown origin 2 2 4
202 Lymphoma 1 1
Sum 155 186 341
A total of 1273 patients with Lynch syndrome including 555 males and 718 females
were followed up.
*Includes both epithelial skin cancer that is often not reported, and sebaceous gland
invasive cancer. This specific diagnosis may not have been uniformly reported from
the different centres.
Table 2 Location of cancers diagnosed prior to inclusion
ICD9 Organ Males Females All
153 Colon 535 446 981
154 Sigmoideum/rectum 96 84 180
182 Endometrium 296 296
183 Ovary 61 61
151 Stomach 5 5 10
152 Duodenum 11 8 19
156 Gall bladder/bile duct 3 1 4
157 Pancreas 2 2 4
189 Urinary bladder 23 27 50
188 Kidney/ureter 16 14 30
173 Skin 21 28 49
174 Breast 46 46
185 Prostate 20 4 24
191 Brain 2 7 9
140 Lip 1 1
146 Pharynx 1 1
150 Oesophagus 2 2
155 Liver 1 1
159 Abdomen unspecified 1 1
161 Mouth 1 1
162 Lung 1 1 2
171 Soft tissue sarcoma 3 7 10
172 Melanoma 1 7 8
180 Cervix 20 20
186 Testes 6 6
190 Eye 2 2
193 Thyroid 2 2
194 Endocrine tumour 1 1 2
199 Unknown origin 3 1 4
200 Haematological malignancies 7 2 9
Sum 764 1071 1835
A total of 1273 patients with Lynch syndrome including 555 males and 718 females
were considered.
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In patients who had cancer before the age of 40, the cumula-
tive incidences for any further cancer by 70 years of age were
high, being 73% for path_MLH1, 76% for path_MSH2 and
52% for path_MSH6 carriers (table 4). The cumulative inci-
dences for CRC as a next cancer were 46% for path_MLH1,
48% for path_MSH2 and lower 23% (p<0.05) for path_MSH6
carriers. Most of these incidences were higher than we have pre-
viously reported in patients with LS without cancer before
inclusion, but not signiﬁcantly so (table 4). Patient numbers did
not allow for reliable calculations of cumulative incidence of
subsequent cancers for path_PMS2 carriers. The limited
numbers of late-occurring LS-associated cancers in the upper GI
tract, urinary tract and brain precluded calculation of cumulative
incidences of extra-CRCs stratiﬁed by genetic variants.
Next, we considered whether or not a previous history of
colon cancer increased the incidence of CRC cancer in patients
with LS. The cumulative incidences from 40 to 70 years were
36% in those having been diagnosed previously with colon
cancer and 39% in those with non-CRCs only before inclusion
(table 5).
Based on the AIRs in online supplementary table S1 and the
algorithms described above, we included the cumulative future
risk for any subsequent cancer or for CRC as a subsequent
cancer for any age up to 70 years as a separate tab in the
website available at http://lscarisk.org.
Time since last colonoscopy to CRC
Time since last colonoscopy to CRC was available for 133
(94%) of the 141 patients in whom the ﬁrst subsequent cancer
was a CRC (table 6). Sixty (46%) of CRCs were diagnosed
within 2 years, and 102 (78%) within 3 years of the last colon-
oscopy. The time distribution of CRC diagnoses did not differ
signiﬁcantly from that observed in patients with LS without pre-
vious cancer(s) (p=0.10; ﬁgure 1). We did note, however, that
patients found to have subsequent CRC in this report had been
colonoscopied according to protocol (with a 1-year, 2-year or
3-year interval) more consistently than were patients prior to
their ﬁrst CRC as reported in our former report.3 Only 9% of
the CRCs were diagnosed 3.5 years or more since last
colonoscopy.
Survival
Without having access to causes of death, we could only calcu-
late crude survival. Since crude survival is more meaningful in
young patients, we restricted survival analysis to patients who
had a subsequent cancer before 65 years of age. Crude 10-year
survival in the whole cohort after any subsequent cancer was
82% (95% CI 76 to 87). In path_MLHI, path_MSH2 or
path_MSH6 carriers, crude 10-year survival was 80% (95% CI
71% to 87%), 84% (95% CI 73% to 90%) and 84% (95% CI
51% to 96%), respectively, with no difference between genetic
Table 4 Calculated cumulative incidence from current age to 70 years, for any subsequent cancer or for colorectal cancer as a subsequent
cancer at 70 years by patient’s current age and genetic variant, and comparison with corresponding incidences previously reported in patients
who had not had cancer before inclusion
Cumulative incidence for any subsequent cancer
at 70 years (95% CI)
Cumulative incidence for colorectal as subsequent
cancer at 70 years (95% CI)
Current age (years) path_MLH1 path_MSH2 path_MSH6 path_MLH1 path_MSH2 path_MSH6
Patients with LS having had previous cancer(s) (this report)
40 73% (66.9% to 79.2%) 76% (68.8% to 82.6%) 50% (33.8% to 66.5%) 46% (37.7% to 54.4%) 48% (38.1% to 58.1%) 23% (7.4% to 37.9%)
50 65% (57.9% to 72.1%) 63% (54.1% to 71.8%) 47% (30.6% to 62.5%) 38% (29.2% to 45.9%) 35% (24.5% to 44.9%) 23% (7.4% to 37.9%)
60 47% (38.2% to 56.0%) 42% (30.8% to 52.8%) 31% (15.4% to 47.0%) 24% (15.8% to 32.2%) 18% (8.2% to 27.3%) 13% (0.7% to 25.1%)
Patients with LS without previous cancer*
40 66% (57.8% to 74.2%) 67% (55.8% to 77.8%) 53% (38.6% to 68.6%) 37% (30.1% to 49.4%) 28% (15.2% to 41.2%) 20% (4.4% to 35.4%)
50 53% (41.9% to 63.6%) 55% (40.4% to 69.0%) 43% (26.4% to 60.2%) 25% (18.0% to 39.6%) 21% (6.9% to 34.1%) 18% (2.8% to 33.8%)
60 32% (17.7% to 45.4%) 33% (14.4% to 51.5%) 24% (5.6% to 42.2%) 13% (4.5% to 27.1%) 14% (0.6% to 27.6%) 11% (2.8% to 33.8%)
Relative cumulative incidence† patients with LS having had previous cancer(s)
40 1.11 (0.96 to 1.29) 1.13 (0.95 to 1.38) 0.94 (0.60 to 1.44) 1.26 (0.93 to 1.77) 1.70‡ (1.09 to 3.24) 1.14 (0.33 to 5.47)
50 1.23 (0.99 to 1.59) 1.15 (0.87 to 1.60) 1.09 (0.63 to 1.91) 1.50 (0.98 to 2.65) 1.69 (0.91 to 5.16) 1.23 (0.35 to 8.40)
60 1.49 (0.98 to 2.71) 1.27 (0.74 to 2.97) 1.29 (0.53 to 5.76) 1.80 (0.88 to 8.62) 1.26 (0.46 to 30.82) 1.17 (0.06 to ∞)
*Calculated from online table in Møller et al 2015.3
†Cumulative incidence in this report divided by cumulative incidence in patients with LS without previous cancer.3
‡None of the cumulative incidences compared besides this one were significantly different (p<0.05).
LS, Lynch syndrome.
Table 5 Calculated cumulative incidences for colorectal cancer from current ages as indicated in left column to 70 years of age for patients
having had colon cancer before inclusion and for patients not having had colon cancer before inclusion
Calculated cumulative incidences of cancers from current age (in left column) to 70 years
Current age (years) Colon cancer prior to inclusion (95% CI) Extracolonic cancers prior to inclusion (95% CI) Relative cumulative incidence*
40 36% (29.0% to 43.8%) 39% (28.5% to 50.2%) 0.92 (0.61% to 1.32%)
50 31% (24.3% to 38.9%) 25% (16.7% to 35.3%) 1.24 (0.78% to 1.90%)
60 19% (13.1% to 27.0%) 15% (6.6% to 23.0%) 1.26 (0.70% to 3.06%)
(95% CI) for all patients irrespective of genetic variant.
*Cumulative incidence patients with colon cancer prior to inclusion divided by cumulative incidence in patients with Lynch syndrome with previous extracolonic cancers only; none of
the differences between the cumulative incidences that we compared reached statistical significance (p>0.05).
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variants (p=0.63; ﬁgure 2). Crude 10-year survival in the
whole series after CRC was 91% (95% CI 83% to 95%), and in
path_MLHI, path_MSH2 or path_MSH6 carriers 89% (95% CI
76% to 95%), 92% (95% CI 77% to 97%) and 100%, respect-
ively, and with no signiﬁcant difference between the pathogenic
variants of the different genes (p=0.44; ﬁgure 3).
DISCUSSION
Our study addressed three critical clinical questions in a large
cohort of LS carriers of pathogenic variants of the MMR genes
who had a history of previous cancer: (i) what is the cumulative
incidence of subsequent cancers, (ii) in which organs will these
subsequent cancers occur; and (iii) what is the survival following
a subsequent cancer? Family G reported by Warthin in 1913
(later demonstrated to carry a path_MSH2 variant) illustrates
the dismal outcome of LS prior to its formal identiﬁcation: 10
out of the 12 females with cancer had ‘cancer uterus’ and none
of them lived to develop a subsequent cancer.5 There is now a
need for better information on what is happening to the
growing number of cancer survivors in order to further
individualise their continued healthcare. Such data are in prin-
ciple not obtainable from retrospective studies, because many
patients in former generations died from their ﬁrst cancers and
because of the ascertainment biases inherent in retrospective
studies. This study is the ﬁrst to present prospective empirical
observations from multiple centres and including sufﬁcient
numbers to meet these needs.
Both CRCs and extra-CRCs continued to occur, and with a
similar or moderately higher incidence compared with patients
with LS who had not had cancer before inclusion (our previous
report, 3). The point estimates that showed a modest increase in
the incidence of cancer in LS cancer survivors compared with
asymptomatic carriers need independent validation. If con-
ﬁrmed, a number of possible causes could be considered, among
which are the impact of distinct penetrance patterns of different
pathogenic variants of the same gene as well as the role of
genetic and/or environmental modiﬁers.6
Patients with previous colon cancer(s) were not at an
increased risk for a subsequent colon cancer when compared
with those with previous extracolonic cancers. Treatment of the
ﬁrst colon cancer is an obvious confounder in this observation:
patients with LS with a ﬁrst colon cancer treated with more
extensive colonic resection reportedly have a lower risk of meta-
chronous CRC than those receiving less extensive surgery.7 8
The current results indicate that we have enough cases of CRCs
subsequent to a previous colon cancer to plan a study on exam-
ining relationship between treatment of previous colon cancer
and incidence of subsequent CRC, and we will expand the data-
base to do so. Also, for the current study we did not have infor-
mation on adenoma identiﬁcation and removal at surveillance
colonoscopy that would enable us to consider the relation
between adenomas detected/removed and subsequent CRC. The
database is currently being expanded to include information on
adenomas to this end, and the results will be reported
separately.
In line with our observations in patients without a previous
history of cancer, non-compliance with surveillance could not
account for the majority of CRCs (table 6 and ﬁgure 1).
A more detailed description of the relationships between time
since last colonoscopy, stage of CRC at diagnosis and survival is
of interest and we are in process of carrying out a further study
to address these questions.
Of note, the incidence of CRC was similar in females and
males, probably reﬂecting a reduced number of endometrial
cancer because of the high proportion of females who had hys-
terectomy for previous endometrial cancer. In female patients
with LS without previous cancer(s), endometrial cancer may be
the ﬁrst cancer and mask the high incidence of colon cancer. As
mentioned above, in retrospective studies of former generations
(family history/segregation analysis) many patients died from
their ﬁrst cancer, some females might have died from a ﬁrst
endometrial cancer, the number of CRCs in females might have
been lower than in males, and this may have been reported as
lower incidence of CRC in females. Regarding other extracolo-
nic cancers, cancers of the urinary tract, upper GI tract includ-
ing pancreas and bile duct, and brain were more frequent in the
present cohort than in MMR mutation carriers with no previous
history of cancer.3 This higher incidence may be associated with
their older age.
Survival was excellent for subsequent CRC (ﬁgure 3), but
slightly worse for any subsequent cancer (ﬁgure 2), suggesting a
worse survival for some extracolonic cancers. Lifetime cumula-
tive incidence of speciﬁc cancers and their associated survival
will need a different set of material and methods, and the
Table 6 Months elapsed between last complete colonoscopy and
diagnosis of CRC
Months since last
colonoscopy
Number
CRC
Cumulative
number CRC
Cumulative
(%)
<6 1 1 1
6–11 12 13 10
12–17 28 41 31
18–23 19 60 45
24–29 29 89 67
30–35 13 102 77
36–42 16 118 89
43–47 3 121 91
48–120 12 133 100
CRC, colorectal cancer.
Figure 1 Result of two-sample t-test of months since last
colonoscopy to colorectal cancer in previous report3 and in this report:
p=0.10.
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database is currently being expanded to report on this separately
and at a later time. Furthermore, the good survival of all pro-
spectively detected cancers in our cohort supports continued
medical follow-up and promotion of cancer awareness, which
may contribute to favourable outcomes in this high-risk group
through early detection and treatment of cancers. In principle,
we should have had a control group without any intervention to
conclude that the favourable survival observed was associated
with our interventions. How to construct such a control group,
if possible, is a challenge for future research.
The present study design has several strengths. It is the ﬁrst
prospective study with power to give reliable estimates on risk
for subsequent cancers in patients with LS and for survival
when it occurs. The methods used adjust for unequal distribu-
tions of ages and are suitable to demonstrate variations related
to age between and within the groups examined. The results
reported here provide a solid basis for statistical power calcula-
tions that will inform the feasibility of relevant studies in this
ﬁeld. The observations analysed and discussed in this report are
summarised in online supplementary table S1 and the corre-
sponding observations in our former report on patients with LS
without cancer prior to inclusion are given in online supplemen-
tary table S1 in our former report.3
Some limitations are also apparent, and the results presented
must be interpreted accordingly. Detailed information on the
management of ﬁrst cancers or precancers that might have
Figure 2 Survival after subsequent
cancer by genetic variants (with 95%
CIs as dotted line in same colour)
when cancer diagnosed <65 years of
age. Dotted lines indicate upper 95%
CIs and broken lines indicate lower
95% intervals. There was no death
observed in path_PMS2 carriers.
Figure 3 Survival after subsequent
colorectal cancer by genetic variant
(with 95% CIs as dotted line in same
colour) when cancer diagnosed
<65 years of age. Dotted lines indicate
upper 95% CIs and broken lines
indicate lower 95% intervals. There
was no death observed in path_MSH6
carriers.
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modiﬁed the incidences reported, as well as the number of
adenomas removed at colonoscopy and their histopathology, are
of interest and will be addressed in further studies.
Conclusions
We have previously reported that most patients with LS survive
their ﬁrst cancer(s).3 Here we report a high incidence of subse-
quent cancers, and that most patients survive their subsequent
cancer(s) as well. While the implementation of successful
follow-up strategies has produced a large and growing cohort of
LS survivors, we still have limited information on what will
happen next to these patients. We will expand our database to
provide more information on what these patients have experi-
enced so far, and we will continue our prospective observations.
We welcome other centres to join us so that we can identify suf-
ﬁcient numbers of patients to address more questions of import-
ance to patients and healthcare professionals.
The results reported here are empirical observations and may
be used for genetic counselling based on the premises given. We
have established an open access interactive website http://
lscarisk.org that may now be helpful for patients with LS both
without and with previous cancers. It includes our prospective
observations and the algorithms described to calculate speciﬁc
cancer risk estimates for any patient with LS. To date, this is the
most comprehensive tool to assess age-related, gene-related and
gender-related cancer risk in patients with LS.
For further information on the collaborating activities please
visit http://insight-group.org/ and http://mallorca-group.org/. To
tailor cancer risk prediction according a given patient’s age,
gender, MMR gene variant and history of previous cancer, visit
http://lscarisk.org.
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